A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome

Inclusion Criteria: * has a diagnosis of IC-BPS according to the American Urological Association endorsed criteria for a duration of ≥6 months to ≤15 years * has IC-BPS with moderate to severe bladder pain and urinary frequency * has urinary frequency of ≥8 voids/day * has had a cystoscopy within 6months before screening with report indicating absence of Hunner lesion(s). A patient who has not had a cystoscopy within 6months may undergo cystoscopy, at the physician's discretion, and be rescreened for study entry. * has persistent symptoms despite an adequate trial of 3 months of dietary counseling and modification * has a body mass index within 18.5 to 39 kg/m2 and a body weight ≥99 lbs. * has non-pharmacologic interventions (such as physical therapy, pelvic floor massage, acupuncture, naturopathy, new initiation of mindfulness exercises, or cognitive behavioral therapy) that are unchanged for a minimum of 30 days before the screening visit * if of childbearing potential, must meet any of the following criteria: * Patients must use 1 form of highly effective contraception with their partners during the entire study period and for 5 months after the last dose of the IMP * Sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. …